Skip to content Skip to sidebar Skip to footer

Newsletter

4 hours ago

Biotech Stocks

Botanix Pharmaceuticals (ASX:BOT) lands Piramal API backup, targets 25% to 40% COGS cut

Botanix de-risks Sofdra supply chain with Piramal as second API source Botanix Pharmaceuticals (ASX:BOT) has taken a meaningful step forward in de-risking its supply chain, securing a second API supplier…

ByCharlie Youlden

Mar 2026

Tech Stocks Technology

Botanix (ASX: BOT) The Bleeding Has Stopped, Now Comes the Hard Part

Cash Burn Slowing, Execution Risk Rising Botanix announced an important update on its supplier payment terms, which gives investors much better visibility around the company’s cash runway. For many investors following…

ByCharlie Youlden

Mar 2026

Tech Stocks Technology

Botanix (ASX:BOT) Is Bleeding Cash, Can Sofdra Save It?

Botanix Pharmaceuticals is the definition of a high-risk, high-reward stock. It has been a year of heavy operating cash burn, driven by a 50-person sales force and high API costs.…

ByCharlie Youlden

Jan 2026

Healthcare Stocks Small Caps Stocks

What happened to Botanix (ASX:BOT) and why are investors sweating

From A$0.53 to A$0.118 Botanix Shows How Fast Biotech Narratives Turn Botanix (ASX:BOT) is a clear example of how quickly sentiment can shift in Australian biotech. The share price has…

ByCharlie Youlden

Jul 2025

Biotech Stocks Healthcare Stocks News Small Caps Stocks

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this magnitude would suggest the FDA knocked back its drug or…